This large retrospective database analysis found recurrent Cdiff was significantly more common in those exposed to a PPI than those not exposed (25% vs 19%) (adjusted hazard ratio 1.42). Risks and benefits of PPI therapy in patients with Cdiff need to be carefully weighed, to reduce the risk of recurrence (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.